The clinical relevance of GALNT14 in chemotherapy resistance has been demonstrated in cisplatin-resistant ovarian cancer models, in which combination therapy targeting both GALNT14 and mTOR signaling promoted cell death [48,80]. This evidence concerns the gene MTOR and ovarian cancer.